Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Harvard Business School

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Litigation Details for Pfizer Inc. v. Ranbaxy Laboratories Limited (D. Del. 2007)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Pfizer Inc. v. Ranbaxy Laboratories Limited (D. Del. 2007)

Small Molecule Drugs cited in Pfizer Inc. v. Ranbaxy Laboratories Limited

Details for Pfizer Inc. v. Ranbaxy Laboratories Limited (D. Del. 2007)

Date Filed Document No. Description Snippet Link To Document
2007-03-09 1 Complaint References Cited U.S. PATENT DOCUMENTS 3,983,140 A 9/1976 Endo et al. 4,231,938 A 11/1980 Monaghan et …double patenting over the ‘080 Patent in light of the disclosure of the ‘893 Patent. The ‘893 Patent discloses…double patenting over the ‘080 Patent in light of the disclosure of the ‘893 Patent. The ‘893 Patent discloses…the ‘574 Patent.v U.S. Patent No. 4 572 909 U.S. Patent No. 4,572,909 (“the ‘909 Patent”) lists the…States Letters Patent Nos. 4,681,893 (“the ‘893 patent”) and 6,455,574 (“the ‘574 patent”). A copy of each External link to document
2007-05-03 15 Opening Brief in Support Novartis has sought to put Teva 5,246,937 (“ 937 patent”); 5,840,763 (“ 763 patent”); to the hard choice… 5,246,937, 5,840,763, 5,866,581, 5,916,893, 118AII(L) Patents …5,866,581 (“ 581 patent”); 5,916,893 (“ 893 patent”); massive liability for patent infringement when… the and 6,124,304 (“ 304 patent”). The 937 patent is 937 patent expires or Teva prevails in…judgment that the patent [listed in the Famvir® Orange Book patents or that the patents Orange External link to document
2007-06-14 21 Reply Brief coating of HZ-blocker granules U.S. Patent No. 5,075,114 (the “ 114 patent”), which © 2007 Thomson/West. … at least three patents-the 340 patent, the 5,229,137 patent, and the 5,989,588 patent. (DX BE.) This …114 patent to the Examiner. (DX D; DX L, Paper No. 14 at 118.) The 114 patent, like the 072 patent, reveals…has conclusively determined that the ‘893 patent (and its patent term extension) is not invalid or unenforceable…Defense To The ’893 Patent Ranbaxy did not make an obviousness challenge to the ‘893 patent at trial in the External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.